Nanosuspension technologies for delivery of poorly soluble drugs

Journal of Nanomaterials

Volumn 2015, Issue , 2015, Pages

  Yadollahi, Roya ^a   Vasilev, Krasimir ^a   Simovic, Spomenka ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; HISTOLOGY; NANOPARTICLES; SOLUBILITY; SURFACE TREATMENT; TISSUE;

AQUEOUS SOLUBILITY; CHARACTERIZATION TECHNIQUES; DRUG FORMULATIONS; HIGH PRESSURE HOMOGENIZATION; POORLY SOLUBLE DRUGS; POST-PROCESSING TECHNIQUES; PREPARATION METHOD; SURFACE MODIFICATION METHODS;

EMULSIFICATION;

EID: 84934970518     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2015/216375     Document Type: Review

References (149)

1. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, "Nano-nization strategies for poorly water-soluble drugs," Drug Discovery Today, vol. 16, no. 7-8, pp. 354-360, 2011.
2. P. Xiaohui, S. Jin, L. Mo, and H. Zhonggui, "Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs," Current Nanoscience, vol. 5, no. 4, pp. 417-427, 2009.
3. S. Mercadante and V. Vitrano, "Pain in patients with lung cancer: pathophysiology and treatment," Lung Cancer, vol. 68, no. 1, pp. 10-15, 2010.
4. C. A. S. Bergström, C. M. Wassvik, K. Johansson, and I. Hubat-sch, "Poorly soluble marketed drugs display solvation limited solubility," Journal of Medicinal Chemistry, vol. 50, no. 23, pp. 5858-5862, 2007.
5. S. K. Bhal, K. Kassam, I. G. Peirson, and G. M. Pearl, "The rule of fve revisited: applying log D in place of log P in drug-likeness flters," Molecular Pharmaceutics, vol. 4, no. 4, pp. 556-560, 2007.
6. C. M. Wassvik, A. G. Holmén, R. Draheim, P. Artursson, and C. A. S. Bergström, "Molecular characteristics for solid-state limited solubility," Journal of Medicinal Chemistry, vol. 51, no. 10, pp. 3035-3039, 2008.
7. G. Piferi and P. Restani, "The safety of pharmaceutical excipients," Il Farmaco, vol. 58, no. 8, pp. 541-550, 2003.
8. A. K. Nayak and P. P. Panigrahi, "Solubility enhancement of etoricoxib by cosolvency approach," ISRN Physical Chemistry, vol. 2012, Article ID 820653, 5 pages, 2012.
9. S. Nippe and S. General, "Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and infuence of stabilising agents," International Journal of Pharmaceutics, vol. 416, no. 1, pp. 181-188, 2011.
10. A. P. Lakshmi, M. A. Kumar, M. V. Krishna, K. A. Vijetha, and G. Ashwini, "Formulation development of irbesartan (poorly water-soluble drug) immediate release tablets," International Research Journal of Pharmacy, vol. 3, pp. 117-120, 2012.
11. M. J. Arias, J. R. Moyano, and J. M. Ginés, "Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding," International Journal of Pharmaceutics, vol. 153, no. 2, pp. 181-189, 1997.
12. S. I. Farag Badawy, M. M. Ghorab, and C. M. Adeyeye, "Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates," International Journal of Pharmaceutics, vol. 128, no. 1-2, pp. 45-54, 1996.
13. M. T. Esclusa-Díaz, M. Guimaraens-Méndez, M. B. Pérez-Marcos, J. L. Vila-Jato, and J. J. Torres-Labandeira, "Characterization and in vitro dissolution behaviour of ketoconazole/β-and 2-hydroxypropyl-β-cyclodextrin inclusion compounds," International Journal of Pharmaceutics, vol. 143, no. 2, pp. 203-210, 1996.
14. T. Jarvinen, K. Jarvinen, N. Schwarting, and V. J. Stella, "β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs," Journal of Pharmaceutical Sciences, vol. 84, no. 3, pp. 295-299, 1995.
15. T. L. Rogers, A. C. Nelsen, J. Hu et al., "A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid," European Journal of Pharmaceutics and Biopharmaceutics, vol. 54, no. 3, pp. 271-280, 2002.
16. C. A. Ventura, S. Tirendi, G. Puglisi, E. Bousquet, and L. Panza, "Improvement of water solubility and dissolution rate of urso-deoxycholic acid and chenodeoxycholic acid by complexation with natural and modifed β-cyclodextrins," International Journal of Pharmaceutics, vol. 149, no. 1, pp. 1-13, 1997.
17. A. G. Floyd, "Top ten considerations in the development of parenteral emulsions," Pharmaceutical Science and Technology Today, vol. 2, no. 4, pp. 134-143, 1999.
18. M. Nakano, "Places of emulsions in drug delivery," Advanced Drug Delivery Reviews, vol. 45, no. 1, pp. 1-4, 2000.
19. M. J. Lawrence and G. D. Rees, "Microemulsion-based media as novel drug delivery systems," Advanced Drug Delivery Reviews, vol. 45, no. 1, pp. 89-121, 2000.
20. M. P. de Oliveira, E. Garcion, N. Venisse, J.-P. Benôit, W. Couet, and J.-C. Olivier, "Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice," Pharmaceutical Research, vol. 22, no. 11, pp. 1898-1905, 2005.
21. M. Moneghini, I. Kikic, D. Voinovich, B. Perissutti, and J. Filipovíc-Grčić, "Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution," International Journal of Pharmaceutics, vol. 222, no. 1, pp. 129-138, 2001.
22. A. Serajuddln, "Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs," Journal of Pharmaceutical Sciences, vol. 88, no. 10, pp. 1058-1066, 1999.
23. N. Zerrouk, C. Chemtob, P. Arnaud, S. Toscani, and J. Dugue, "In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions," International Journal of Pharmaceutics, vol. 225, no. 1-2, pp. 49-62, 2001.
24. G. C. S. Rao, M. S. Kumar, N. Mathivanan, and M. E. B. Rao, "Nanosuspensions as the most promising approach in nano-particulate drug delivery systems," Pharmazie, vol. 59, no. 1, pp. 5-9, 2004.
25. R. H. Müller, "Nanosuspension for the i.v. administration of poorly soluble drugs-stability during sterilization and longterm storage," in Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials, pp. 574-575, 1995.
26. R. Becker, R. H. Muller, B. Kruss, and K. Peters, "Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution," US Patent, No. 5858410, 1999.
27. G. G. Liversidge, K. C. Cundy, J. F. Bishop, and D. A. Czekai, "Surface modifed drug nanoparticles," US Patent no. 5145684, 1992.
28. P. Gassmann, M. List, A. Schweitzer, and H. Sucker, "Hydrosols-alternatives for the parenteral application of poorly water soluble drugs," European Journal of Pharmaceutics and Biophar-maceutics, vol. 40, no. 2, pp. 64-72, 1994.
29. R. H. Müller, C. Jacobs, and O. Kayser, "Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future," Advanced Drug Delivery Reviews, vol. 47, no. 1, pp. 3-19, 2001.
30. R. H. Müller, K. Peters, R. Becker et al., "Nanosuspensions-a novel formulation for the IV administration of poorly soluble drugs," in Proceedings of the 1st World Meeting of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, APGI, Budapest, Hungary, 1995.
31. R. H. Muller, K. Peters, R. Becker, and B. Kruss, "Nanosuspen-sions for the i.v. administration of poorly soluble drugs: stability during sterilization and long-term storage," Proceedings of the Controlled Release Society, no. 22, pp. 574-575, 1995.
32. R. H. Muller, R. Becker, B. Kruss, and K. Peters, "Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution," US Patent 5, 858, 410, 1999.
33. G. P. Sanganwar, S. Sathigari, R. J. Babu, and R. B. Gupta, "Simultaneous production and co-mixing of microparticles of nevi-rapine with excipients by supercritical antisolvent method for dissolution enhancement," European Journal of Pharmaceutical Sciences, vol. 39, no. 1-3, pp. 164-174, 2010.
34. D. Zhang, T. Tan, L. Gao, W. Zhao, and P. Wang, "Preparation of azithromycin nanosuspensions by high pressure homoge-nization and its physicochemical characteristics studies," Drug Development and Industrial Pharmacy, vol. 33, no. 5, pp. 569-575, 2007.
35. Y. Zhang, N. Kohler, and M. Zhang, "Surface modifcation of superparamagnetic magnetite nanoparticles and their intracel-lular uptake," Biomaterials, vol. 23, no. 7, pp. 1553-1561, 2002.
36. E. Blanco, C. W. Kessinger, B. D. Sumer, and J. Gao, "Multifunctional micellar nanomedicine for cancer therapy," Experimental Biology and Medicine, vol. 234, no. 2, pp. 123-131, 2009.
37. Y. Matsumura and K. Kataoka, "Preclinical and clinical studies of anticancer agent-incorporating polymer micelles," Cancer Science, vol. 100, no. 4, pp. 572-579, 2009.
38. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, "A theoretical basis for a biopharmaceutic drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability," Pharmaceutical Research, vol. 12, no. 3, pp. 413-420, 1995.
39. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue, "Formulation design for poorly water-soluble drugs based on biopharmaceutics classifcation system: basic approaches and practical applications," International Journal of Pharmaceutics, vol. 420, no. 1, pp. 1-10, 2011.
40. M. Martinez, L. Augsburger, T. Johnston, and W. W. Jones, "Applying the biopharmaceutics classifcation system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations," Advanced Drug Delivery Reviews, vol. 54, no. 6, pp. 805-824, 2002.
41. F. Kesisoglou, S. Panmai, and Y. Wu, "Nanosizing-oral formulation development and biopharmaceutical evaluation," Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 631-644, 2007.
42. G. J. Vergote, C. Vervaet, I. van Driessche et al., "An oral controlled release matrix pellet formulation containing nanocrys-talline ketoprofen," International Journal of Pharmaceutics, vol. 219, no. 1-2, pp. 81-87, 2001.
43. M. V. Chaubal, "Application of formulation technologies in lead candidate selection and optimization," Drug Discovery Today, vol. 9, no. 14, pp. 603-609, 2004.
44. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, "Nanosizing: a formulation approach for poorly-water-soluble compounds," European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113-120, 2003.
45. J. Hu, K. P. Johnston, and R. O. Williams III, "Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs," Drug Development and Industrial Pharmacy, vol. 30, no. 3, pp. 233-245, 2004.
46. G. G. Liversidge, K. C. Cundy, J. F. Bishop, and D. A. Czekai, "Surface modifed drug nanoparticles," US Patents 5, 145, 689, 1992.
47. J. Chingunpituk, "Nanosuspension technology for drug delivery," Walailak Journal of Science and Technology, vol. 4, no. 2, pp. 139-153, 2007.
48. S. Bansal, M. Bansal, and R. Kumria, "Nanocrystals: current strategies and trends," International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 3, no. 1, pp. 406-419, 2012.
49. J.-U. A. H. Junghanns and R. H. Müller, "Nanocrystal technology, drug delivery and clinical applications," International Journal of Nanomedicine, vol. 3, no. 3, pp. 295-309, 2008.
50. J. Moschwitzer, G. Achleitner, H. Pomper, and R. H. Müller, "Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology," European Journal of Pharmaceutics and Biopharmaceu-tics, vol. 58, no. 3, pp. 615-619, 2004.
51. Y.-J. Chen, X.-L. Yang, X.-L. Zhao, and H.-B. Xu, "Preparation of oleanolic acid nanosuspension," Zhongguo Yaoxue Zazhi, vol. 41, no. 12, pp. 924-927, 2006.
52. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amighi, "Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine," International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 167-177, 2005.
53. M. P. Kumar, Y. M. Rao, and S. Apte, "Improved bioavailability of albendazole following oral administration of nanosuspension in rats," Current Nanoscience, vol. 3, no. 2, pp. 191-194, 2007.
54. P. Langguth, A. Hanafy, D. Frenzel et al., "Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound," Drug Development and Industrial Pharmacy, vol. 31, no. 3, pp. 319-329, 2005.
55. R. H. Müller and C. Jacobs, "Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability," International Journal of Pharmaceutics, vol. 237, no. 1-2, pp. 151-161, 2002.
56. L. Gao, D. Zhang, and M. Chen, "Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system," Journal of Nanoparticle Research, vol. 10, no. 5, pp. 845-862, 2008.
57. R. H. Muller, C. Jacobs, and O. Kayser, "Nanosuspensions for the formulation of poorly soluble drugs," in Pharmaceutical Emulsions and Suspensions, vol. 105, pp. 383-407, 2000.
58. K. P. Krause, O. Kayser, K. Mäder, R. Gust, and R. H. Müller, "Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation," International Journal of Pharmaceutics, vol. 196, no. 2, pp. 169-172, 2000.
59. A. Kumar, S. K. Sahoo, P. Globale et al., "Review on solubility enhancement techniques for hydrophobic drugs," Pharmacie Globale, vol. 3, no. 3, pp. 001-007, 2011.
60. G. A. Reddy, "Nanosuspension technology-a review," IJPI's Journal of Pharmaceutics and Cosmetology, vol. 2, no. 8, pp. 47-52, 2012.
61. C. M. Keck and R. H. Müller, "Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation," European Journal of Pharmaceutics and Biopharmaceutics, vol. 62, no. 1, pp. 3-16, 2006.
62. A. Lemke, A. F. Kiderlen, B. Petri, and O. Kayser, "Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas," Nano-medicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 4, pp. 597-603, 2010.
63. A. Hanafy, H. Spahn-Langguth, G. Vergnault et al., "Pharma-cokinetic evaluation of oral fenofbrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug," Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 419-426, 2007.
64. C. Jacobs and R. H. Müller, "Production and characterization of a budesonide nanosuspension for pulmonary administration," Pharmaceutical Research, vol. 19, no. 2, pp. 189-194, 2002.
65. N. Hernández-Trejo, O. Kayser, H. Steckel, and R. H. Müller, "Characterization of nebulized buparvaquone nanosuspen-sions-efect of nebulization technology," Journal of Drug Targeting, vol. 13, no. 8-9, pp. 499-507, 2005.
66. C. Jacobs, O. Kayser, and R. H. Müller, "Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone," International Journal of Pharmaceutics, vol. 214, no. 1-2, pp. 3-7, 2001.
67. K. Peters, S. Leitzke, J. E. Diederichs et al., "Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efcacy in murine Mycobacterium avium infection," Journal of Antimicrobial Chemotherapy, vol. 45, no. 1, pp. 77-83, 2000.
68. M. A. Kassem, A. A. Abdel Rahman, M. M. Ghorab, M. B. Ahmed, and R. M. Khalil, "Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs," International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 126-133, 2007.
69. L. Gao, D. Zhang, M. Chen et al., "Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions," International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 321-327, 2008.
70. S. Ben Zirar, A. Astier, M. Muchow, and S. Gibaud, "Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice," European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 2, pp. 649-656, 2008.
71. C. Jacobs, O. Kayser, and R. H. Müller, "Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide," International Journal of Pharmaceutics, vol. 196, no. 2, pp. 161-164, 2000.
72. R. Xiong, W. Lu, J. Li, P. Wang, R. Xu, and T. Chen, "Preparation and characterization of intravenously injectable nimodipine nanosuspension," International Journal of Pharmaceutics, vol. 350, no. 1-2, pp. 338-343, 2008.
73. O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Crof, "Formulation of amphotericin B as nanosuspension for oral administration," International Journal of Pharmaceutics, vol. 254, no. 1, pp. 73-75, 2003.
74. W. Sun, S. Mao, Y. Shi, L. C. Li, and L. Fang, "Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and efect of particle size on oral absorption," Journal of Pharmaceutical Sciences, vol. 100, no. 8, pp. 3365-3373, 2011.
75. R. H. Müller, S. Gohla, and C. M. Keck, "State of the art of nano-crystals-special features, production, nanotoxicology aspects and intracellular delivery," European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 1, pp. 1-9, 2011.
76. B. K. Nanjwadea, G. K. Derkar, H. Bechra, and F. V. Manvi, "Nanosized technological approaches for the delivery of poorly water soluble drugs," Iranian Journal of Pharmaceutical Sciences, vol. 6, no. 3, pp. 149-162, 2010.
77. A. Akkar and R. H. Müller, "Intravenous itraconazole emulsions produced by SolEmuls technology," European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, no. 1, pp. 29-36, 2003.
78. P. Kocbek, S. Baumgartner, and J. Kristl, "Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs," International Journal of Pharmaceutics, vol. 312, no. 1-2, pp. 179-186, 2006.
79. M. Trotta, M. Gallarate, F. Pattarino, and S. Morel, "Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions," Journal of Controlled Release, vol. 76, no. 1-2, pp. 119-128, 2001.
80. P. Dandagi, S. Kerur, V. Mastiholimath, A. Gadad, and A. Kulkarni, "Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution," Iranian Journal of Pharmaceutical Research, vol. 8, no. 2, pp. 79-86, 2009.
81. W. Mehnert and K. Mäder, "Solid lipid nanoparticles: production, characterization and applications," Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 165-196, 2001.
82. P. Ahlin, J. Kristl, and J. Šmid-Korbar, "Optimization of procedure parameters and physical stability of solid lipid nanoparti-cles in dispersions," Acta Pharmaceutica, vol. 48, no. 4, pp. 259-267, 1998.
83. S. Bosselmann and R. O. Williams III, "Route-specifc challenges in the delivery of poorly water-soluble drugs," in Formulating Poorly Water Soluble Drugs, R. O. Williams III, A. B. Watts, and D. A. Miller, Eds., pp. 1-2, Springer, New York, NY, USA, 2012.
84. V. B. Patravale, A. A. Date, and R. M. Kulkarni, "Nanosuspen-sions: a promising drug delivery strategy," Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 827-840, 2004.
85. S. Verma and D. Burgess, "Solid nanosuspensions: the emerging technology and pharmaceutical applications as nanomedicine," in Pharmaceutical Suspensions, A. K. Kulshreshtha, O. N. Singh, andG.M. Wall, Eds., pp. 285-318, Springer, New York, NY, USA, 2010.
86. E. M. Merisko-Liversidge and G. G. Liversidge, "Drug nanopar-ticles: formulating poorly water-soluble compounds," Toxicologic Pathology, vol. 36, no. 1, pp. 43-48, 2008.
87. Y. Wang, D. Zhang, Z. Liu et al., "In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery," Nanotechnology, vol. 21, no. 15, Article ID 155104, 2010.
88. P. Mhatre, R. Chinchole, U. Desai, and R. Chavan, "Review: nanosuspensions," International Journal of Pharmaceutical Sciences Review and Research, vol. 13, no. 1, pp. 118-124, 2012.
89. H. G. Merkus, "Dynamic light scattering," in Particle Size Measurements, pp. 299-317, Springer, 2008.
90. V. Teeranachaideekul, V. B. Junyaprasert, E. B. Souto, and R. H. Müller, "Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology," International Journal of Pharmaceutics, vol. 354, no. 1-2, pp. 227-234, 2008.
91. M. Gaumet, A. Vargas, R. Gurny, and F. Delie, "Nanoparticles for drug delivery: the need for precision in reporting particle size parameters," European Journal of Pharmaceutics and Bio-pharmaceutics, vol. 69, no. 1, pp. 1-9, 2008.
92. J. Chingunpitak, S. Puttipipatkhachorn, P. Chavalitshewin-koon-Petmitr, Y. Tozuka, K. Moribe, and K. Yamamoto, "Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method," Drug Development and Industrial Pharmacy, vol. 34, no. 3, pp. 314-322, 2008.
93. L. Lindfors, P. Skantze, U. Skantze, J. Westergren, and U. Olsson, "Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth," Langmuir, vol. 23, no. 19, pp. 9866-9874, 2007.
94. R. F. Domingos, M. A. Baalousha, Y. Ju-Nam et al., "Characterizing manufactured nanoparticles in the environment: multimethod determination of particle sizes," Environmental Science and Technology, vol. 43, no. 19, pp. 7277-7284, 2009.
95. E. Haustein and P. Schwille, "Fluorescence correlation spec-troscopy: novel variations of an established technique," Annual Review of Biophysics and Biomolecular Structure, vol. 36, pp. 151-169, 2007.
96. V. Filipe, A. Hawe, and W. Jiskoot, "Critical evaluation of nano-particle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates," Pharmaceutical Research, vol. 27, no. 5, pp. 796-810, 2010.
97. N. Manh Tang, H. Geckeis, J. I. Kim, and H. P. Beck, "Application of the fow feld fow fractionation (FFFF) to the characterization of aquatic humic colloids: evaluation and optimization of the method," Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 181, no. 1, pp. 289-301, 2001.
98. A. Lapresta-Fernández, A. Salinas-Castilloa, S. Anderson de la Llana et al., "A general perspective of the characterization and quantifcation of nanoparticles: imaging, spectroscopic, and separation techniques," Critical Reviews in Solid State and Materials Sciences, vol. 39, no. 6, pp. 423-458, 2014.
99. M. G. Fakes, B. J. Vakkalagadda, F. Qian et al., "Enhancement of oral bioavailability of an HIV-attachment inhibitor by nano-sizing and amorphous formulation approaches," International Journal of Pharmaceutics, vol. 370, no. 1-2, pp. 167-174, 2009.
100. K. Kawakami, "Modifcation of physicochemical characteristics of active pharmaceutical ingredients and application of super-saturatable dosage forms for improving bioavailability of poorly absorbed drugs," Advanced Drug Delivery Reviews, vol. 64, no. 6, pp. 480-495, 2012.
101. F. Tian, J. A. Zeitler, C. J. Strachan, D. J. Saville, K. C. Gordon, and T. Rades, "Characterizing the conversion kinetics of carba-mazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy," Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 2, pp. 271-280, 2006.
102. J. M. Chalmers and G. Dent, Vibrational Spectroscopic Methods in Pharmaceutical Solid-State Characterization, Wiley-VCH, Weinheim, Germany, 2006.
103. Y. Ikeda, Y. Ishihara, T. Moriwaki, E. Kato, and K. Terada, "A novel analytical method for pharmaceutical polymorphs by terahertz spectroscopy and the optimization of crystal form at the discovery stage," Chemical & Pharmaceutical Bulletin, vol. 58, no. 1, pp. 76-81, 2010.
104. M. Otsuka, J.-I. Nishizawa, J. Shibata, and M. Ito, "Quantitative evaluation of mefenamic acid polymorphs by terahertz-chemo-metrics," Journal of Pharmaceutical Sciences, vol. 99, no. 9, pp. 4048-4053, 2010.
105. L. Bond, S. Allen, M. C. Davies et al., "Diferential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials," International Journal of Pharmaceutics, vol. 243, no. 1-2, pp. 71-82, 2002.
106. B. van Eerdenbrugh, L. Froyen, J. A. Martens et al., "Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling," International Journal of Pharmaceutics, vol. 338, no. 1-2, pp. 198-206, 2007.
107. Y. Gao, Z. Li, M. Sun et al., "Preparation, characterization, phar-macokinetics, and tissue distribution of curcumin nanosuspen-sion with TPGS as stabilizer," Drug Development and Industrial Pharmacy, vol. 36, no. 10, pp. 1225-1234, 2010.
108. J. Shi, Literature Review of Steric Stabilization, Center for Industrial Sensors and Measurements, Ohio State University, 2002.
109. S. R. Deshiikan and K. D. Papadopoulos, "Modifed Booth equation for the calculation of zeta potential," Colloid and Polymer Science, vol. 276, no. 2, pp. 117-124, 1998.
110. Y. Liang and J. Binner, "Efect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions," Ceramics International, vol. 34, no. 2, pp. 293-297, 2008.
111. T. Chaurasia, D. Singh, and D. S. Nimisha, "A review on nano-suspensions promising drug delivery strategy," Current Pharma Research, vol. 3, no. 1, pp. 764-776, 2012.
112. D. Quintanar-Guerrero, A. Ganem-Quintanar, E. Allémann, H. Fessi, and E. Doelker, "Infuence of the stabilizer coating layer on the purifcation and freeze-drying of poly(D, L-lactic acid) nanoparticles prepared by an emulsion-difusion technique," Journal of Microencapsulation, vol. 15, no. 1, pp. 107-119, 1998.
113. R. H. Muller and C. M. Keck, "Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles," Journal of Biotechnology, vol. 113, no. 1-3, pp. 151-170, 2004.
114. B. E. Rabinow, "Nanosuspensions in drug delivery," Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 785-796, 2004.
115. Y.-X. Zhao, H.-Y. Hua, M. Chang, W.-J. Liu, Y. Zhao, and H.M. Liu, "Preparation and cytotoxic activity of hydroxycamp-tothecin nanosuspensions," International Journal of Pharmaceutics, vol. 392, no. 1-2, pp. 64-71, 2010.
116. H. Lamb, Hydrodynamics, Cambridge University Press, Cambridge, UK, 6th edition, 1993.
117. Y. Liu, P. Xie, D. Zhang, and Q. Zhang, "A mini review of nanosuspensions development," Journal of Drug Targeting, vol. 20, no. 3, pp. 209-223, 2012.
118. R. H. Muller, J. Moschwitzer, and F. N. Bushrab, "Manufacturing of nanoparticles by milling and homogenization techniques," in Nanoparticle Technology for Drug Delivery (Drugs and the Pharmaceutical Sciences), vol. 159, pp. 21-51, CRC Press, New York, NY, USA, 2006.
119. B. van Eerdenbrugh, G. van den Mooter, and P. Augustijns, "Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products," International Journal of Pharmaceutics, vol. 364, no. 1, pp. 64-75, 2008.
120. V. E. Bernard, V. Sofe, M. Johan A et al., "Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-a case study with itraconazole," European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 2, pp. 590-596, 2008.
121. W. C. N. Charman and V. J. Stella, Lymphatic Transport of Drugs, CRC Press, Boca Raton, Fla, USA, 1992.
122. J. P. K. Tan, Q. Wang, and K. C. Tam, "Control of burst release from nanogels via layer by layer assembly," Journal of Controlled Release, vol. 128, no. 3, pp. 248-254, 2008.
123. O. Kayser, "A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications," International Journal of Pharmaceutics, vol. 214, no. 1-2, pp. 83-85, 2001.
124. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, "Factors afecting the clearance and biodistribution of polymeric nanoparticles," Molecular Pharmaceutics, vol. 5, no. 4, pp. 505-515, 2008.
125. J. Lode, I. Fichtner, J. Kreuter, A. Berndt, J. E. Diederichs, and R. Reszka, "Infuence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models," Pharmaceutical Research, vol. 18, no. 11, pp. 1613-1619, 2001.
126. N. Z. Wu, D. Da, T. L. Rudoll, D. Needham, A. R. Whorton, and M. W. Dewhirst, "Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue," Cancer Research, vol. 53, no. 16, pp. 3765-3770, 1993.
127. J. Kreuter, V. E. Petrov, D. A. Kharkevich, and R. N. Alyaut-din, "Infuence of the type of surfactant on the analgesic efects induced by the peptide dalargin afer its delivery across the blood-brain barrier using surfactant-coated nanoparticles," Journal of Controlled Release, vol. 49, no. 1, pp. 81-87, 1997.
128. F. Gabor, C. Fillafer, L. Neutsch, G. Ratzinger, and M. Wirth, "Improving oral delivery," in Handbook of Experimental Pharmacology, vol. 197 of Drug Delivery, pp. 345-398, 2010.
129. S. V. Sastry, J. R. Nyshadham, and J. A. Fix, "Recent technological advances in oral drug delivery. A review," Pharmaceutical Science and Technology Today, vol. 3, no. 4, pp. 138-145, 2000.
130. Y. Chen, J. Liu, X. Yang, X. Zhao, and H. Xu, "Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective efect," Journal of Pharmacy and Pharmacology, vol. 57, no. 2, pp. 259-264, 2005.
131. T. Venkatesh, A.K. Reddy, J. Uma Maheswari, M. Deena Dalith, and C. K. Ashok Kumar, "Nanosuspensions: ideal approach for the drug delivery of poorly water soluble drugs," Der Pharmacia Lettre, vol. 3, no. 2, pp. 203-213, 2011.
132. N. Arunkumar, M. Deecaraman, and C. Rani, "Nanosuspension technology and its applications in drug delivery," Asian Journal of Pharmaceutics, vol. 3, no. 3, pp. 168-173, 2009.
133. Y. Shi, W. Porter, T. Merdan, and L. C. Li, "Recent advances in intravenous delivery of poorly water-soluble compounds," Expert Opinion on Drug Delivery, vol. 6, no. 12, pp. 1261-1282, 2009.
134. K. K. Jain, "Drug delivery systems-an overview," Methods in Molecular Biology, vol. 437, pp. 1-50, 2008.
135. S. Bhalla, "Parenteral drug delivery," in Gibaldi's Drug Delivery Systems in Pharmaceutical Care, M. Lee and A. Desai, Eds., p. 107, ASHP, Bethesda, Md, USA, 2007.
136. H. Lou, X. Zhang, L. Gao et al., "In vitro and in vivo antitumor activity of oridonin nanosuspension," International Journal of Pharmaceutics, vol. 379, no. 1-2, pp. 181-186, 2009.
137. L. Borgström, "The importance of the device in asthma therapy," Respiratory Medicine, vol. 95, supplement B, pp. S26-S29, 2001.
138. H. M. Courrier, N. Butz, and T. F. Vandamme, "Pulmonary drug delivery systems: recent developments and prospects," Critical Reviews in Terapeutic Drug Carrier Systems, vol. 19, no. 4-5, pp. 425-498, 2002.
139. X. Liao and T. S. Wiedmann, "Solubilization of cationic drugs in lung surfactant," Pharmaceutical Research, vol. 20, no. 11, pp. 1858-1863, 2003.
140. M. Beck-Broichsitter, "Pulmonary drug delivery with nanopar-ticles," in Nanomedicine in Health and Disease, R. J. Hunter and V. R. Preedy, Eds., pp. 229-248, CRC Press, New York, NY, USA, 2011.
141. S. Dhiman, T. G. Singh, and Dharmila, "Nanosuspension: a recent approach for nano drug delivery system," International Journal of Current Pharmaceutical Research, vol. 3, no. 4, pp. 96-101, 2011.
142. M. M. Bailey and C. J. Berkland, "Nanoparticle formulations in pulmonary drug delivery," Medicinal Research Reviews, vol. 29, no. 1, pp. 196-212, 2009.
143. K. A. Foster, M. Yazdanian, and K. L. Audus, "Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium," Journal of Pharmacy and Pharmacology, vol. 53, no. 1, pp. 57-66, 2001.
144. R. Gaudana, J. Jwala, S. H. S. Boddu, and A. K. Mitra, "Recent perspectives in ocular drug delivery," Pharmaceutical Research, vol. 26, no. 5, pp. 1197-1216, 2009.
145. H. Gupta, M. Aqil, R. K. Khar, A. Ali, A. Bhatnagar, and G. Mittal, "Sparfoxacin-loaded PLGA nanoparticles for sustained ocular drug delivery," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 2, pp. 324-333, 2010.
146. R. C. Nagarwal, S. Kant, P. N. Singh, P. Maiti, and J. K. Pandit, "Polymeric nanoparticulate system: a potential approach for ocular drug delivery," Journal of Controlled Release, vol. 136, no. 1, pp. 2-13, 2009.
147. R. Pignatello, C. Bucolo, G. Spedalieri, A. Maltese, and G. Puglisi, "Flurbiprofen-loaded acrylate polymer nanosuspen-sions for ophthalmic application," Biomaterials, vol. 23, no. 15, pp. 3247-3255, 2002.
148. S. Das and P. K. Suresh, "Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B," Nanomedicine: Nanotechnol-ogy, Biology, and Medicine, vol. 7, no. 2, pp. 242-247, 2011.
149. S. Gupta, M. K. Samanta, and A. M. Raichur, "Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efcacy," AAPS Pharm-SciTech, vol. 11, no. 1, pp. 322-335, 2010.